# REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®)

> **NCT00127842** · PHASE4 · COMPLETED · sponsor: **Amgen** · enrollment: 110 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Etanercept

## Key facts

- **NCT ID:** NCT00127842
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2005-08
- **Final completion:** 2009-09
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2014-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00127842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00127842, "REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®)". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00127842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*